Thanks to Prof. Tarun Khanna of Harvard Business School for this interview with Pharma Paragon Dr.Yusuf Hamied. This interview was held in 2013 and Dr.Hamied had prophesied that in 2020, India will feel the real impact of patent law. In view of that he had said that he would be willing to pay the originator the suitable compensation but India should not be deprived of newer drugs and be at the mercy of the innovators. To keep up to his words Dr.Hamied has gone into a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of Remdesivir. Under this agreement, Cipla can manufacture the API and the finished formulation and market it in 127 countries under its own brand name. This effort made by Dr.Hamied has an humanitarian angle to save lives of patients suffering from the current pandemic.
